脉血康胶囊对缺血性脑卒中二级预防的效果

Effect of Maixuekang capsule on secondary prevention of ischemic stroke

目的观察脉血康胶囊对缺血性脑卒中二级预防的效果。方法选取2013年1月至2015年3月于厦门市第二医院神经内科门诊就诊及住院治疗的缺血性脑卒中患者248例，采用随机数字表法分为观察组（124例）和对照组（124例）。2组患者均给予阿司匹林肠溶片和阿托伐他汀钙片治疗，观察组在此基础上加用脉血康胶囊2粒／次，3次／d。2组疗程均为12个月。观察2组心脑血管事件的发生率，治疗前后总胆固醇、三酰甘油、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、纤维蛋白原水平的变化和不良反应的发生情况。结果治疗12个月后，观察组脱落4例，对照组脱落3例。观察组与对照组患者脑出血发生率差异无统计学意义（P〉0．05），缺血性脑卒中复发率差异有统计学意义[2．5％（3／120）比9．1％（11／121），χ2=4．763，P=0．029]。治疗前2组患者总胆固醇、三酰甘油、LDL-C、HDL-C水平比较，差异均无统计学意义（均P〉0．05）。治疗12个月后，观察组总胆固醇、LDL-C水平明显低于对照组[（3．4±0．6）mmol／L比（3．8±0．8）mmol／L、（2．1±0．6）mmol／L比（2．2±0．6）mmol/L]，HDL-C水平明显高于对照组[（1．46±0．42）mmol／L比（1．23±0．25）mmol／L]，差异均有统计学意义（均P〈0．01），2组间三酰甘油水平差异无统计学意义（P〉0．05）。治疗前2组纤维蛋白原水平比较，差异无统计学意义（P〉0．05）。治疗12个月后，观察组纤维蛋白原水平明显低于对照组[（2．4±1．0）g/L比（3．8±1．0）g/L]，差异有统计学意义（P〈0．01）。2组不良反应发生率比较，差异无统计学意义（P〉0．05）。结论脉血康胶囊可调节血脂，降低纤维蛋白原水平，明显减少缺血性脑卒中的复发率。

Objective To explore the effect of Maixuekang capsule on the secondary prevention of ische- mic stroke. Methods Totally 248 patients with ischemic stroke were enrolled from January 2013 to March 2015 in No. 2 Hospital Xiamen. The patients were randomly divided into observation group and control group, with 124 cases in each group. Both groups had aspirin and atorvastatin calcium; the observation group had Maixuekang capsule 2 grain/time, 3 times/d for 12 months. Levels of total cholesterol（TC） , triacylglycerol（ TG）, low density lipoprotein cholesterol（LDL-C）, high density lipoprotein cholesterol（HDL-C） and fibrinogen were tested. Inci- dences of cardiovascular and cerebrovascular events and adverse reactions were recorded. Results The incidenceof cerebral hemorrhage showed no significant difference between observation group （120 cases） and control group （121 cases） during 12 months of treatment（ P 〉 0. 05 ） ; the incidence of ischemic stroke in observation group was significantly lower than that in control group[2.5% （3/120） vs 9.1% （ 11/121 ） ,χ2 =4. 763 ,P =0. 0291. Serum levels of TC, TG, LDL-C, HDL-C and fibrinogen showed no significant differences between groups before treat- ment（ P 〉0.05 ） ; TC, LDL-C and fibrinogen levels in observation group were significantly lower and the HDL-C level was significantly higher than those in control group after 12 months of treatment [ （ 3.4 ± 0.6 ） mmol/L vs （3.8±0.8）mmol/L, （2. 1 ±0.6）mmol/L vs （2.2 ±0.6）mmol/L, （1.46 ±0.42）mmol/L vs （1.23 ± 0.25）mmol/L] （P 〈 0.01 ）. Before treatment, there was no statistic difference of fibrinogen between the two groups（ P 〉 0.05 ）. The levels of fihrinogen decreased significantly in observation group compared with control group[ （2.4 ± 1.0） g/L vs （3.8 ± 1.0） g/El after 12 months treatment, and the difference showed statistical significance（P 〈 0.01 ）. The adverse reaction incidences showed no significant difference between groups （P 〉 0. 05 ）. Conclusion Maixuekang capsule can regulate blood lipid, lower fibrinogen level and reduce the recun＇ence rate of ischemic stroke.